Author: Guan Yanqing

From July 7th to 8th, there were three happy events in the lymphoma community—

span>The opening of the 2022 China Lymphoma Conference, the first meeting of the Lymphoma Committee of the First National Cancer Center for Quality Control was held, and the release of “Malignant Lymphoma Diagnosis and Treatment (Second Edition)” span>. Sponsored by the Lymphoma Expert Group of the Oncology Branch of the Chinese Medical Association, the Rare Cancer Special Committee of the Chinese Clinical Oncology Association, and the Southern Cancer Clinical Research Association, and organized by Sichuan Cancer Hospital and Sun Yat-Sen University Cancer Center, “ 2022 POST-ASCO Conference Information Exchange & Chinese Lymphoma Conference & Rare Tumor Conference” is the largest academic feast in the field of lymphoma in China.

During the conference, an exclusive interview with a reporter from “Physician Daily”Chairman of the conference, Professor Lin Tongyu of Sichuan Cancer Hospital. He expects that cutting-edge research in the field of clinically significant lymphoma can enter clinical practice as soon as possible, and effectively help patients benefit.

“Physician Daily”: Compared with previous conferences, what are the highlights of this conference?

Professor Lin Tongyu:Since the outbreak of COVID-19 in early 2020, this is the first online and offline Chinese Lymphoma Conference. It used to be held in the cloud. The offline communication of experts in the field of lymphoma can generate more sparks of thinking collision, and only by meeting face-to-face can problems be discussed and practical experience passed on. Medicine needs inheritance to innovate, and unity to develop. Therefore, I think this conference is a conference of “inheritance, innovation, unity and development”.

The Physician’s Journal: This conference presents the latest research in all areas of lymphoma. In your opinion, what should be paid attention to when applying these studies to the clinic?

Professor Lin Tongyu: The research presented at this conference is mainly divided into two categories. The first category is research from enterprises, we will pay attention to the efficacy of drugs in clinical trials, the toxic and side effects and doses in Chinese patients. At the same time, we also need to consider pharmacoeconomics. For example, a drug that increases the CR rate from 70% to 74% benefits only a small subset of the population, and the drug is expensive.

Another type of research is researcher-initiated, which is generally under-appreciated due to less publicity , but there are also many studies with practical significance. For example, one study found that radiation doses of only 24 Gy were sufficient for patients with indolent lymphoma, and no higher doses were needed. We expect that these clinically meaningful studies will receive more attention from the industry.

“Physician’s Daily”: In your opinion, what should be paid attention to when applying foreign research to domestic patients?

Professor Lin Tongyu: First, how much curative effect the research actually brings. Second, explore suitable doses for Chinese patients. Many foreign studies focus on the Caucasian population, and the dose application is relatively high. The third is pharmacoeconomics. China is still a developing country, not so rich, and money should be used where the knife is. Don’t always think that everyone’s 1.2 million needles are used for all the push, can they afford it? Make it affordable for all Chinese people. Therefore, we should consider various factors.

“Physician’s Daily”: In recent years, the diagnosis and treatment of lymphoma in my country has been gradually standardized, but there is still a gap between the top three hospitals and primary hospitals. How to solve it?

Professor Lin Tongyu:In December last year, the Lymphoma Quality Control Expert Committee of the National Cancer Quality Control Center was established to promote Standardize the quality of lymphoma diagnosis and treatment, and promote the standardization of tumor diagnosis and treatment nationwide. The primary task of our work is to select demonstration units in six major regions of the country, to drive the development of each region, and to realize the diagnosis and treatment of lymphoma in my country. Standardize, homogenize, and standardize to improve the survival rate and quality of life of patients with lymphoma tumors.

The meeting also attached great importance to the standardization of lymphoma diagnosis and treatment. On July 7, The first offline meeting of the Lymphoma Committee of the National Cancer Center for Quality Control was successfully held for the first time, more than 200 experts from my country Suggestions and suggestions for the standardization of lymphoma diagnosis and treatment. Another major event is that, through the joint efforts of more than 200 experts, “Malignant Lymphoma Diagnosis and Treatment (Second Edition)” was officially published. The level of lymphoma in China needs to be continuously advanced and in line with the world in order to continuously improve the level of lymphoma diagnosis and treatment in my country.